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The epithelial-to-mesenchymal transition (EMT) process allows the trans-differentiation 
of a cell with epithelial features into a cell with mesenchymal characteristics. This process 
has been reported to be a key priming event for tumor development and therefore EMT 
activation is now considered an established trait of malignancy. The transcriptional and 
epigenetic reprogramming that governs EMT has been extensively characterized and 
reviewed in the last decade. However, increasing evidence demonstrates a correlation 
between metabolic reprogramming and EMT execution. The aim of the current review 
is to gather the recent findings that illustrate this correlation to help deciphering whether 
metabolic changes are causative or just a bystander effect of EMT activation. The 
review is divided accordingly to the catabolic and anabolic pathways that characterize 
carbohydrate, aminoacid, and lipid metabolism. Moreover, at the end of each part, we 
have discussed a series of potential metabolic targets involved in EMT promotion and 
execution for which drugs are either available or that could be further investigated for 
therapeutic intervention.
Keywords: epithelial-to-mesenchymal transition, metabolic reprogramming, warburg metabolism, OXPHOS, TCA 
cycle, oncometabolites, amino acid, lipids
Abbreviations: ACC, acetyl-CoA carboxylase; ACSLs, acyl-CoA synthetases; AMF, autocrine motility factor; CAFs, 
cancer-associated fibroblasts; CAIX, carbonic anhydrase IX; CerS6, ceramide synthase 6; CHC, α-cyano-4-hydroxycinnamate; 
ChREBP, carbohydrate-responsive element-binding protein; CSC, cancer stem cell; DHA, docosahexaenoic acid; ECM, 
extracellular matrix; EMT, epithelial-to-mesenchymal transition; ETC, electron transport chain; FAs, fatty acids; FASN, fatty 
acid synthase; FBP1, fructose-1,6-bisphosphatase; FH, fumarate hydratase; GDH, glutamate dehydrogenase; GLS, glutaminase; 
GLUT, glucose transporter; GSK-3β, glycogen synthase kinase 3β; d-2HG, d-2-hydroxyglutarate; HGF, hepatocyte growth 
factor; HIF-1α, hypoxia-inducible factor-1α; HK2, hexokinase; IDH, isocitrate dehydrogenase; IL-8, interleukin-8; α-KG, 
α-ketoglutarate; LDs, lipid droplets; LDH, lactate dehydrogenase; MCTs, monocarboxylate transporters; ME1, malic enzyme 1; 
MET, mesenchymal-to-epithelial transition; MMPs, matrix metalloproteases; mtROS, mitochondrial reactive oxygen species; 
NHE1, sodium-proton exchange 1; NSCLC, non-small cell lung cancer; O-GlcNAc, O-linked N-acetyl-glucosamine; OXPHOS, 
oxidative phosphorylation; PDAC, pancreatic ductal adenocarcinoma; PDH, pyruvate dehydrogenase; PDK4, pyruvate dehy-
drogenase kinase 4; PGI, glucose phosphate isomerase; PM, plasma membrane; PK, pyruvate kinase; PPARGC1A/PGC-1α, 
peroxisome proliferator-activated receptor gamma coactivator 1 alpha; PPP, pentose phosphate pathway; SAH, S-adenosyl 
homocysteine; SAM, S-adenosyl methionine; SCD, stearoyl-CoA desaturase-1; SDH, succinate dehydrogenase; SIRT, sirtuin; 
SOD2, superoxide dismutase 2; SREBPs, sterol regulatory element-binding proteins; TAGs, triacylglicerols; TCA, tricarboxylic 
acid; TDH, threonine dehydrogenase; TET1, ten–eleven translocation 1; TGF-β, transforming growth factor-β; TGIF2, TGF-β-
induced factor homeobox 2; TKTL1, transketolase-like protein 1 isoform; TNBC, triple-negative breast cancer; TNF-α, tumor 
necrosis factor-α; TUFM, TU translation elongation factor mitochondrial; VEGF, vascular endothelial growth factor.
FiGURe 1 | General features of epithelial-to-mesenchymal transition (eMT). The transition of epithelial cells toward a mesenchymal phenotype, induced by 
several environmental or soluble factors, is characterized by the loss of cell–cell contact and cell polarity, which disrupts the epithelial architecture and endows the 
mesenchymal cells with migratory and invasive competences. EMT is accompanied by the modulation of well-known markers, among which the loss of epithelial 
marker E-cadherin, induced by the upregulation of its transcriptional repressors (i.e., Snail1/2, Twist, ZEB1/2), is one of the priming event. The concomitant 
acquisition of mesenchymal markers sustains and stabilizes the newly acquired phenotype.
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iNTRODUCTiON
The epithelial-to-mesenchymal transition (EMT) process 
allows the trans-differentiation of a cell with epithelial features 
into a cell with mesenchymal characteristics (Figure  1). This 
process has an essential role in physiological conditions (e.g., 
development, wound healing, and stem cell maintenance) and 
has been extensively reported to contribute pathologically to 
fibrosis and cancer progression. Interestingly, cells can also 
undergo the mesenchymal-to-epithelial transition (MET) 
process. MET is also essential in physiological conditions 
(e.g., during embryogenesis) but a key role in the formation 
of secondary metastases was reported (1, 2). The focus of the 
current review is on EMT in cancer progression although this 
process shares common characteristic with the physiological 
EMT program. The molecular mechanisms that an epithelial 
cell undergoes during EMT are tightly regulated and influenced 
by the cell-to-cell signaling network and by environmental 
factors. Independently of the stimuli that induce EMT, loss of 
E-cadherin is considered the key event and Snail1, Snail2 (also 
known as Slug), Twist, and ZEB1 are established transcription 
factors that can regulate E-cadherin expression. These mecha-
nisms have been elegantly reviewed in Ref. (3). Conversely, the 
metabolic rewiring that sustains an epithelial cell undergo-
ing EMT has been poorly investigated. However, since the 
metabolic reprogramming is now considered a hallmark of 
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cancer (4), increasing evidence links metabolic deregulation 
to EMT program. This review gathers the recent findings on 
EMT and metabolic reprogramming in cancer and discusses 
how targeting certain metabolic pathways/hubs may impact 
on EMT and therefore on cancer progression.
MeTABOLiC PATHwAYS THAT  
CONTROLS eMT
Targeting Carbohydrates Metabolic 
Reprogramming in eMT
Non-proliferating differentiated cells preferentially metabolize 
glucose to pyruvate through glycolysis and then oxidize this 
pyruvate via the tricarboxylic acid (TCA) cycle and subsequent 
oxidative phosphorylation (OXPHOS). This maximizes the 
efficiency of ATP generation from a single molecule of glucose. 
Otto Warburg first described that most cancer cells show 
increased glucose conversion into lactate even in oxygen-rich 
condition (aerobic glycolysis) (5). Aerobic glycolysis allow 
proliferating cell to satisfy three basic needs of cells in rapid divi-
sion: (i) fast ATP; (ii) carbohydrates redirection to biosynthetic 
pathways; and (iii) cellular redox status homeostasis (6). As a 
direct consequences of a net increase in glucose consumption, 
many cancers exhibit abnormal lactic acid release and a more 
acidic extracellular pH (pHe) (7). Moreover, high level of lactate 
correlates with metastases of several types of human cancers (8). 
In this scenario, it is not surprising that hypoxia, low pHe, and 
glucose utilization are established features of many solid tumors 
and concur to EMT and cancer dissemination. Thus, interfering 
with the glycolytic pathway could impair EMT and subsequent 
tumor progression and could be a potential anticancer strategy. 
However, to our knowledge, none of glycolysis inhibitors that 
have shown promising results in preclinical models are currently 
used in the clinic.
Several glycolytic enzymes have been found associated with 
invadopodia structures, protrusions of the plasma membrane 
(PM) that have a major role in extracellular matrix (ECM) deg-
radation, and metastasis (9). In addition, the glycolytic-derived 
ATP is the main source for cell survival during metastatic 
dissemination (10, 11). Several papers indeed show a strict 
correlation between transforming growth factor-β (TGF-β)-
induced EMT, glycolytic switch, and repression of mitochondrial 
function (12, 13). Dong et al. have demonstrated that in breast 
cancer, loss of fructose-1,6-bisphosphatase together with the loss 
of E-cadherin promote cancer stem cell (CSC)-like properties 
and cancer cell dissemination by enhancing β-catenin signal-
ing and EMT program. These events are concomitant with the 
induction of glycolysis, increase of glucose uptake, and inhibi-
tion of oxygen consumption (14). Additionally, EMT induction 
in breast cancer cells is paralleled by the expression of glucose 
transporters, lactate dehydrogenase (LDH), monocarboxylate 
transporters (MCTs), and glycogen phosphorylase isoforms, 
key players in sustaining enhanced aerobic glycolysis (15). 
Moreover, the acquisition of a malignant and chemo-resistant 
phenotype is associated with EMT and aerobic glycolysis in 
gastric cancer (16).
The importance of glycolysis for EMT is also reinforced by 
a metabolite profiling approach conducted in pancreatic ductal 
adenocarcinoma (PDAC) cells. This profiling identified three 
main subpopulations with different phenotypes: interestingly, 
the clone that is enriched for glycolytic-related metabolites is 
characterized by a mesenchymal phenotype. Since mesenchymal 
properties are positive correlated with cancer aggressiveness 
and diseases progression, the study reinforced the functional 
relevance of glycolytic metabolism in disease progression (17). In 
addition, the exposure of PDAC cells to established EMT induc-
ers [i.e., tumor necrosis factor-α (TNF-α) and TGF-β] increases 
glucose uptake and lactate secretion, without affecting OXPHOS 
metabolism (18).
Glycolytic metabolism has been also associated to CSC, 
a phenotype that shares common molecular pathways with 
EMT, and characterizes the cells that within the tumor tissue 
are responsible for tumor repopulation, therapy resistance, and 
relapse in several cancer types (19). However, contradictory 
results described the CSC metabolic phenotype as glycolytic 
or OXPHOS addicted not only in various tumor types, but also 
within individual cancer types. Some studies have postulated 
that glycolysis supports the self-renewal ability of CSCs by 
maintaining low ROS levels (19, 20) and in line with this 
glucose deprivation reduces the number of CSCs in in  vitro 
studies (21). In addition, the enhancement of the glycolytic 
flux has been shown to be paralleled by a decrease in mito-
chondrial metabolism (i.e., TCA cycle and OXPHOS) with 
respect to their differentiated counterparts (22–26). Gammon 
et  al. demonstrated that the CSC fraction of head and neck 
squamous cell carcinoma that undergoes hypoxia-induced 
EMT is characterized by glycolysis, a reduction in the oxygen 
consumption rate and decreased mitochondrial mass and ROS 
levels (27). Notably, Dong et al. demonstrated the concomitant 
acquisition of CSC-like properties, EMT, and induction of 
glycolysis following fructose-bisphosphatase 1 silencing in 
breast cancer (14).
We now proceed analyzing the principal players involved in 
sustaining the Warburg metabolism with a particular focus on the 
transporters and glycolytic enzymes whose deregulation has been 
linked to the acquisition of EMT traits and subsequent enhanced 
metastatic potential in cancer cells.
Hypoxia
In fast-growing solid cancers, the inner zone of the tumor becomes 
progressively hypoxic and acid. These environmental inputs 
drive the expression and stabilization of the hypoxia-inducible 
factor-1α (HIF-1α). HIF-1α is responsible for the transcriptional 
activation of genes involved in the restoration of local oxygen 
perfusion and in the enhancement of the glycolytic flux (28, 29). 
In addition to its canonical role, HIF-1α is able to regulate the 
expression of matrix metalloproteases (MMPs) (30) and several 
hypoxia-inducible EMT-related genes (31) such as Snail1, Slug, 
and Twist. In addition, HIF-1α regulates the autocrine motility 
factor (AMF), the secreted form of the glycolytic enzyme glucose 
phosphate isomerase (PGI). AMF ectopic expression triggers 
EMT in breast cancer cells (32). Since hypoxia is a well-known 
inducer of EMT in epithelial cancers, such as PDAC  (33), 
FiGURe 2 | The metabolic features of epithelial-to-mesenchymal transition (eMT). Several components of the molecular pathways driving EMT have a clear 
impact on cell metabolism and vice versa, resulting in a metabolic rewiring which sustains the EMT transcriptional program. EMT-committed cancer cells could rely 
on an aerobic glycolytic metabolism or could shift toward the more efficient oxidative phosphorylation (OXPHOS), dependent on tumor type and/or tumor stage. 
Here, we have highlighted in red circles/ellipses EMT transcriptional factors that are affected by the metabolites reported in different tumor types.
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hepatocellular (34), ovarian (35), and lung cancers (36), we 
can speculate that this may be partially due to the metabolic 
reprogramming orchestrated by HIF-1α. More recently, also in 
glioblastoma, it has been demonstrated that HIF-1α silencing is 
able to prevent EMT induced by the hypoxic microenvironment 
(37). Studies from our laboratory have shown that cancer-asso-
ciated fibroblasts (CAFs) promote EMT of prostate cancer cells 
through an ROS-dependent HIF-1α stabilization. This transition 
is paralleled by the acquisition of stem-like and metastatic traits 
of cancer cell (38, 39). In keeping, hypoxic senescent fibroblasts, 
which display a CAF-like phenotype with increased lactate pro-
duction, are also capable of promoting EMT in prostate cancer 
cells (40). Due to its important roles, HIF-1α is a potential target 
for anticancer therapy. Among the molecules described to be able 
to target HIF-1α (41), the compounds BAY87-2243, an inhibi-
tor of its activity and stability, and the antisense oligonucleotide 
EZN-2968 entered phase I clinical trials (42). Hypoxia induces 
EMT not only via the transcriptional regulation of HIF-1α-
dependent EMT genes but also via epigenetic mechanism of 
gene regulation (Figure 2). Indeed, HIF-1α is able to increase the 
expression of ten–eleven translocation 1 (TET1), which catalyzes 
the conversion of 5-methylcytosine to 5-hydroxymethylcytosine, 
thus inducing DNA demethylation. Hypoxia-induced expression 
of TET1 promotes EMT by complexing with HIF-1α and HIF-1β 
and activating the transcriptional activation of HIF-dependent 
EMT genes (43, 44).
Glucose Transporters
The glucose transporters 1 (GLUT1) and GLUT3 are transcrip-
tionally induced by HIF-1, thus coupling the hypoxia with 
increased glucose uptake and glycolysis (45). Interestingly, 
overexpression of GLUT1 increases MMP-2 expression/activity 
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and invasiveness of cancer cell (46). Moreover, GLUT3 expres-
sion correlates with both EMT markers (i.e., vimentin, Snail, Slug, 
ZEB1, ZEB2, Twist1) and glucose uptake in non-small cell lung 
cancer (NSCLC) cells (47). In addition, enhanced GLUT1 and/or 
GLUT3 expression is associated with poor prognosis in several 
type of human tumors (48). Numerous efforts have been made to 
test the efficacy of GLUT inhibitors as anticancer drugs: WZB117 
and the natural flavonoid silibinin are under preclinical studies 
even if to our knowledge no specific GLUT1 inhibitors have been 
identified.
Lactate
Since lactate is the by-product of Warburg-dependent metabo-
lism and increase of glycolysis is reported in several carcinomas, 
high levels of lactate are positively correlate with cancer aggres-
siveness in several tumors (8, 49). In many types of tumor 
a significant proportion of pyruvate is reduced into lactate, a 
reaction catalyzed by LDH5. Elevated LDH5 expression cor-
relates with unfavorable prognosis in many human tumors and 
silencing of LDH5 impairs tumor initiation and progression 
(50–53). According to the pivotal role exerted by lactate in 
the promotion of the metastatic process, lactate can induce 
the upregulation of TGF-β2 expression (54), which in turn 
induces a mesenchymal pro-migratory phenotype of glioblas-
toma cells and promotes MMP-2 activation, ECM remodeling, 
and metastasis formation (55). It has also been reported that 
lactate is able to induce the production of TGF-β1 in  vivo 
(56). In keeping, it has been shown that lactate administration 
promotes in  vitro migration of human breast carcinoma cells 
as well as experimental lung metastases in mice intraperito-
neally injected with lactate (57). Lactate is also a sensor of 
NAD+/NADH ratio, which is crucial for activity of the sirtuins 
histone deacetylase, a class of NAD+-dependent enzymes that 
possess either mono-ADP-ribosyltransferase or deacetylase 
activity (58). High levels of NAD+/NADH ratio correlate with 
energy stress and promote sirtuins activity. Some studies show 
that SIRT1 induces both EMT and metastasis by suppressing 
E-cadherin transcription (59, 60). Furthermore, our group has 
recently shown that CAF-induced lactate production increases 
activity of SIRT1 with consequent deacetylation/activation of 
peroxisome proliferator-activated receptor gamma coactivator 1 
alpha (PPARGC1A, also known as PGC-1α), a master regulator 
of mitochondrial biogenesis. This activation is crucial for the 
achievement of EMT. Accordingly, PGC-1α silencing abolishes 
invasion and EMT of prostate cancer cells. This evidence shows 
LDH as a possible therapeutic anticancer target. Several dif-
ferent classes of inhibitor have been synthesized, such as the 
gossypol derivative FX-11, compound GNE-140, galloflavin, 
and others (61), although none of these molecules are under 
consideration in the clinic.
Monocarboxylate Transporters
Key elements of the lactate shuttles are the MCTs, being MCT4 
mainly involved in export of lactate and MCT1 in the uptake 
of this catabolite. Several studies demonstrated that silencing or 
inhibition of MCT1 and MCT4 are able to decrease the migra-
tion and invasion of several cancer cells (62–65). In particular, 
Fiaschi et  al. have demonstrated that silencing of MCT1 and 
inhibition of MCT1-mediate lactate upload by prostate cancer 
cells impairs tumor growth and lung micrometastasis formation 
(66). Indeed, the blockade of lactate import and/or export is 
an interesting target for alternative therapeutic approaches. 
The α-cyano-4-hydroxycinnamate (CHC), that targets MCTs, 
has been used successfully in preclinical models without major 
toxicity in  vivo (67–69). The AstraZeneca MCT1 inhibitor 
AZD3965 is in phase I/II clinical trials in the United Kingdom. 
Importantly, MCT4 silencing was shown to reduce tumor 
cell migration in  vitro and in  vivo (62) and the AstraZeneca 
MCT4 inhibitor (AZ93) has been reported as an highly effi-
cient and likely selective compound that is currently used in 
preclinical studies.
Acidity
The regulation of lactate transport directly impacts on extracel-
lular acidity and, together with the increase of the glycolytic flux 
lead to an unbalance in pH gradient across PM of cancer cells. 
Indeed, it is well established that tumor tissue are characterized 
by low pHe and the role of tumor acidity in cancer invasion 
and metastasis is well recognized (70). Indeed, low pHe leads 
to apoptosis of normal tissue at the periphery of the tumor 
while generating a positive selective pressure on cancer cells, 
selecting subclones that are resistant to acidic environment. 
Furthermore, acidification promotes angiogenesis through the 
enhanced expression of the vascular endothelial growth factor 
(VEGF) (71) and interleukin-8 (72) induces adherens junctions 
dissociation (73) and ECM degradation and remodeling (70, 74). 
Moreover, low pHe is crucial for the metastasization process 
providing secretion/activation of idrolases, such as catepsin (75) 
and MMPs (76). Acidic pHe was found to induce EMT in human 
melanoma cells (77) and in Lewis lung carcinoma cells (78). 
Accordingly, exposure of tumor cells to an acidic environment 
prior to tail vein injection increases lung colonization in a model 
of experimental metastasis (79).
Several molecules act as key players of cancer-associated 
extracellular acidification, such as the sodium-proton exchange 1 
(NHE1), carbonic anhydrase IX (CAIX), the sodium bicarbonate 
transporter 1, and anion exchange 2. These molecules are possible 
targets for therapy focused on disruption of acid–base balance in 
cancer cells. In particular, CAIX, a membrane bound isoform of 
CA transcriptionally regulated by HIF-1α, induces extracellular 
acidification catalyzing the CO2 hydration and its overexpres-
sion is associated with increased metastasis and poor patients 
survival in several cancers (80). Fiaschi et al. have shown that 
activation of CAIX in CAFs leads to an extracellular acidification 
that enhances MMP-2 and MMP-9 secretion, thereby driving 
the stromal-induced EMT in prostate cancer cells. Moreover, 
both genetic silencing and pharmacological inhibition of CAIX 
are sufficient to impede EMT and CAF-induced invasion of 
prostate cancer cells (81). Furthermore, CAIX silencing in 
CAFs decreases prostate cancer cell tumor growth and lung 
micrometastasis formation, indicating the enzyme as an ideal 
target for anticancer therapy. At the moment, indisulam, an 
inhibitor of CAIX is tested in clinical trials for the treatment 
of NSCLC (82).
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Glycolytic Enzymes
Glycolysis is finely regulated and articulated in 10 different steps 
and this could offer an array of potential targets to impair the EMT 
process. Moreover, the presence of several potential targets allows 
the possibility to interfere with more steps, either simultaneously 
or sequentially. Blocking EMT and metabolic reprogramming 
could therefore be a potential successful therapeutic approach. 
Hexokinase (HK2) is a HIF-1 target gene that controls the first 
rate-limiting step of glycolysis and is often overexpressed in 
cancer (83–86). It has been recently reported that breast CSCs 
showed increased HK2 expression and glycolytic rate. Notably, 
the glycolytic inhibitor, 2-deoxyglucose counteracts breast 
cancer cells undergoing EMT in a dose dependent fashion (87, 
88). Furthermore, lonidamine that targets mitochondria-bound 
HK is now tested in phase II–III clinical trials (89). The HIF-1 
dependent PGI/AMF (see above) acts as a pro-metastatic sign-
aling molecule, due to its ability to promote tumor migration, 
invasion, and metastasis (90–92). Indeed, PGI/AMF overexpres-
sion leads to EMT achievement through NF-κB activation and 
increased expression of Snail1, ZEB1, and ZEB2 (Figure  2), 
downregulation of miR-200s with concomitant loss of E-cadherin 
(93). In keeping with these observations, high PGI levels in the 
serum positively correlate with metastases in colorectal, esopha-
geal squamous cell, and lung tumors (94–96). However, although 
PGI has an established pro-tumorigenic role, to our knowledge, 
no selective inhibitors are available for preclinical investigation.
Another potential target of the glycolytic cascade is aldolase 
that converts the fructose-1,6-bisphosphate to glyceraldehyde-
3-phosphate and dihydroxyacetone phosphate. The aldolase 
A isoenzyme is commonly overexpressed in various cancers 
(97, 98) and its upregulation has been reported to induce lung 
carcinoma cell migration and EMT by decreasing the expression 
of E-cadherin and concomitantly increasing those of fibronectin 
and vimentin (97).
In addition to the aforementioned glycolytic enzymes, eno-
lase-1 has been recently proposed as a therapeutic target for 
gene-based therapy. The overexpression of enolase-1 increases 
glycolysis, proliferation, migration, and invasion in NSCLC 
cells, a process that is in part mediated by the regulation of 
EMT genes (99). Indeed, silencing of enolase-1 impaired EMT 
execution as shown by Snail1 and N-cadherin downregulation 
and the concomitant increase of E-cadherin expression (99). 
A  role for enolase-1 in promoting migration and invasion has 
been described also in endometrial carcinoma (100). Small-
molecule inhibitors of enolase are available but none of them 
has entered in the clinical practice (101). Finally, the pyruvate 
kinase (PK) enzyme has been recently emerged as an important 
player in tumor progression. PK catalyzes the dephosphorylation 
of phosphoenolpyruvate into pyruvate, resulting in ATP produc-
tion. Differentiated cells primarily express the M1 isoform of the 
PK enzyme, whereas tumor cells often express the embryonic 
M2 isoform, which can be expressed as a tetramer, in its active 
form, or as a dimer with lower affinity for phosphoenolpyruvate. 
Dimeric PKM2 (102) acts as a transcriptional coactivator of HIF-
1α in cancer cells, thus promoting glycolysis (103). Recently, our 
group demonstrated a peculiar role of PKM2 in inducing EMT 
in prostate cancer cells. Indeed, soluble factors secreted by CAF 
induce in prostate cancer the oxidation and phosphorylation of 
PKM2 prompting the nuclear translocation of the enzyme and 
its association with HIF-1α and the differentially expressed in 
chondrocyte-1, a transcriptional repressor, which downregulates 
miR-205. This transcriptional complex induces EMT execution 
(through the upregulation of ZEB2 and Snail1), as well as the 
metabolic rewiring of cancer cells toward OXPHOS metabolism 
(39). To further corroborate the link between PKM2 and EMT, 
Hamabe et al. recently demonstrated that EMT stimulates nuclear 
translocation of PKM2 and subsequent interaction with the TGF-
β-induced factor homeobox 2, which promotes histone H3K9 
deacetylation and the subsequent downregulation of E-cadherin 
expression (104). The PKM2 inhibitor TLN-232 was assessed 
for cancer therapy in a phase II clinical trial but despite some 
initial promising results the recruitment for a second phase II 
trial has halted for legal reasons in 2010 (105). Other efforts have 
been made to identify novel small-molecule inhibitors selective 
for PKM2 (106). However, emerging data suggest that, at least 
some tumors do not require PKM2 (107, 108), thus lowering the 
interest about the targeting of PKM2 in cancer.
Moreover, the switch between PKM1 and PKM2 couples gly-
colysis to pentose phosphate pathway (PPP), a metabolic pathway 
parallel to glycolysis that partially oxidizes glucose to pentoses 
and generates NADPH. The PPP has been described to support 
tumor cell proliferation (109) and to counteract ROS production, 
due to the generation of NADPH. Indeed, several studies show 
that PPP is necessary to handle the enhancement of ROS levels 
in stress condition, such as anchorage independent growth and 
anoikis (110, 111). Despite the PPP has a role in invasion, little is 
known about its contribution to EMT. Indeed, scanty data have 
shown that 6-phophogluconate dehydrogenase downregulation 
reduces in  vitro migration of lung carcinoma cells (112) and 
high expression of the transketolase-like protein 1 isoform was 
positively correlated with invasion and metastasis of several 
carcinoma (113–116).
In addition, the hexosamine biosynthetic pathway (117), that 
accounts for 2–5% of total glucose metabolism and is intimately 
interconnected with the glycolytic pathway, shows a correlation 
with EMT. Indeed, glucose that enters the glycolytic pathway 
can be diverted to produce O-linked N-acetyl-glucosamine 
(O-GlcNAc), a molecule that has a signaling and structural 
role in the cells (117). It has been demonstrated that the addi-
tion of an O-GlcNAc motif at serine 112 prevented Snail1 
O-phosphorylation-mediated degradation thus promoting its 
stabilization (118), thereby providing a direct molecular link 
between glucose metabolism and EMT.
impact of Amino Acids Metabolism on 
eMT and Targeting Approaches
Glucose dependency of fast-growing tumor is paralleled by the 
higher amino acids requirements of these aggressive cancers. 
Indeed, targeting amino acid metabolism is now considered 
a potential therapeutic approach in many cancer types (119). 
Particularly, the role of glutamine in cancer progression has 
been extensively investigated due to the fact that glutamine is 
an essential amino acid for proliferating tumor cells. Glutamine 
can enter the oxidative TCA cycle, contribute to reductive 
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carboxylation, and alter the NADPH production and redox bal-
ance. Glutaminase (GLS) catabolized glutamine conversion into 
glutamate, which is then oxidized by glutamate dehydrogenase 
(GDH) into α-ketoglutarate (α-KG), an intermediate of the TCA 
cycle. Silencing of GLS1 or impairing glutamine metabolism were 
able to counteract the induction of EMT mediated by growth 
factors (e.g., TGF-β) in breast and colon cancers by increasing 
Snail1-targeting miRNA expression and hence impacting on 
Snail stability (Figure 2). Importantly, GLS1 silencing impaired 
tumor growth and metastases formation (120). Moreover, since 
GDH was reported to control tumor aggressiveness and therapy 
response (121), Liu and colleagues hypothesized a link between 
GDH expression/activity and EMT. Indeed, they reported an 
association of GDH overexpression with metastasis formation 
and poor prognosis in colorectal cancer patients. These effects 
were demonstrated to be dependent, at least in  vitro, on the 
EMT induction mediated by GDH/STAT3 axis (122). However, 
Aguilar and colleagues reported a differential contribution of 
amino acid metabolism to EMT. Indeed, prostate cancer cells 
that were selected to display a stable EMT phenotype uncoupled 
to CSC behaviors were shown to (i) reduce the consumption 
rate of glutamine and other ketogenic amino acids (i.e., leucine, 
isoleucine, lysine, threonine, tyrosine, tryptophan, and phe-
nylalanine) and (ii) be less sensitive to glutamine metabolism 
inhibition (123). The differences observed may be due to the fact 
that the model used was peculiar and CSC and EMT programs 
were uncoupled. Indeed, it is usually difficult to distinguish 
whether the metabolic alterations observed in CSC are depend-
ent of EMT or CSC states, since recent studies have found that 
the acquisition of CSC properties may occur in cancer cells 
independently of EMT (124).
Drugs that target glutamine transport into the cell or the 
conversion to α-KG have been designed and tested. GLS 
inhibitors have shown positive results in preclinical models; 
bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl) ethyl sulfide 
impairs cancer cells growth in  vitro and in  vivo (125, 126), 
the GLS inhibitor CB-839 is effective against triple-negative 
breast cancer (TNBC) and hematological tumors in preclinical 
studies (127, 128) and is currently moved on to clinical trials 
(129). Therefore, targeting GLS could be an effective strategy to 
block the EMT process and therefore impair invasive abilities of 
aggressive cancer cells (130).
An alternative source of amino acids in cancer cell is due 
to degradation and recycling of cellular components (e.g., 
autophagy). A role for protein degradation in controlling EMT 
has been postulated recently by investigating how interfering 
with lysosomal cathepsin proteases (i.e., lysosomal-dependent 
protein turnover) affects TGF-β-induced EMT. Indeed, Kern 
and colleagues found increased lysosome activity during EMT 
of mammary epithelial cells derived from the MMTV-PyMT 
mouse model and showed that cathepsin inhibitor E64d 
was able to impair TGF-β-induced EMT and invasion (131). 
Moreover, Akalay and coworkers reported that tumor cells 
undergoing EMT-induced autophagy regulate target recogni-
tion and lysis of cytotoxic T lymphocytes and may be exploited 
for immunotherapeutic strategies to block immune escape 
(132). However, conflicting results revealed that liver-specific 
autophagy-deficient mice showed reduced expression levels 
of epithelial-related genes and increased of the mesenchymal 
related suggesting a direct link between autophagy and EMT. 
Indeed, induction of autophagy degrades Snail1 thus inhibiting 
the TGF-β-mediated EMT (133). This inverse correlation was 
also reported for glioblastoma cells (134). The diverging results 
may be ascribed to the different models used; however the link 
between autophagy and EMT seems to be conceivable. Recently, 
this connection has been further reinforced by the demonstra-
tion that cadherin-6 (Figure  2), a type 2 cadherin that marks 
cells that undergo EMT and correlates with metastatic ability 
in papillary thyroid cancers, restrains autophagy, and promotes 
reorganization of mitochondrial network (135). Autophagy tar-
geting via hydroxychloroquine has now moved into clinical trials 
and a recent review (136) discusses how inducing or inhibiting 
autophagy can be achieved in preclinical models.
Finally, amino acid-related metabolic pathways control 
the EMT process via epigenetic modifications. Indeed, the 
methionine synthesis pathway plays a pivotal role in controlling 
promoters’ methylation and subsequent gene expression regula-
tion. DNA methyltransferases and histone methyltransferases 
transfer a methyl group from the S-adenosyl methionine (SAM) 
to DNA or to positive charged amino acidic residues of histones 
with the formation of the by-product S-adenosyl homocysteine 
(SAH) (137). Since SAH inhibits DNA methyltransferases and 
histone methyltransferases, the ratio between SAM and SAH 
is important for regulating DNA and histone methylation 
(138). Threonine, glycine, and serine are the amino acids 
that sustain SAM generation through the folate metabolism 
(139). Threonine dehydrogenase converts threonine into gly-
cine and acetyl-CoA and together with methionine adenosyl 
transferase are the key enzymes involved in SAM biosynthesis. 
Since methionine adenosyl transferase can be localized into 
the nucleus, it provides an effective system for chromatin-
localized biosynthesis of metabolites to allow an adequate and 
well-organized regulation of the histone and DNA methylation 
processes. This mechanism can be exploited for targeting the 
epigenetic regulation of EMT-related genes. Indeed, SAM-
competitive inhibitors and SAH hydrolase inhibitors have been 
shown to inhibit the methyltransferase EZH2 thus impairing 
the overall methylation histone status leading to transcription 
reactivation of silenced genes, such as the EMT-related gene 
E-cadherin (140, 141).
impact of Lipid Metabolism on eMT 
and Targeting Approaches
Despite glucose and glutamine alterations have been extensively 
investigated in the context of cancer metabolism, increasing 
evidence are now pointing to a pivotal role of alterations to 
lipid-associated pathways (142, 143). Indeed, proliferating can-
cer cells are characterized by increased lipids and cholesterol 
dependency, which can be fulfilled by either increasing the 
upload of exogenous lipids or by over-activating their endog-
enous synthesis. The excess of lipids in cancer cells are stored in 
lipid droplets (LDs) and high LDs and stored-cholesteryl ester 
content in tumors are now considered as hallmarks of cancer 
aggressiveness (144).
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Lipids encompass a vast class of biomolecules of unique 
chemical structure. Among their multiple biological functions, 
they contribute to cell compartmentalization, cell signaling, 
protein trafficking, membrane organization, and energy storage 
and production. Despite their established role in regulating a 
variety of processes during cancer development (145–147), little 
is known about the impact of lipid composition and metabolism 
during EMT.
A lipidomic approach performed on prostate cancer cells that 
underwent EMT following TNFα treatment revealed a significant 
increase in the synthesis of triacylglicerols (TAGs), sustained by 
a concomitant upregulation of fatty acid synthase (FASN) (148). 
It is conceivable that the newly synthesized TAGs, stored into 
LDs, may act not only as a reservoir of energy, but also of fatty 
acids (FAs), which could serve for protein modification, cell 
membrane remodeling, and the generation of pro-tumorigenic 
signals which support EMT-induced cell motility. In keeping 
with the increase of FASN during EMT, administration of the 
FASN inhibitor osthole to the MCF7 breast cancer cells abol-
ishes cell scattering, EMT execution, migration, and invasion 
induced by the hepatocyte growth factor (149). In addition, in 
breast cancer cells undergoing EMT an increased expression of 
FASN resulted in saturated FAs accumulation, which are then 
relocated to the cell membrane and regulate lipid rafts organi-
zation, resulting in the activation of the EMT-inducer VEGF/
VEGFR2 signaling (150).
Although the above-described reports deal with a supporting 
role of FASN-driven lipogenesis for EMT and cell migration, 
opposing observations are also described in the literature. The 
exposure of NSCLC cells to the EMT-inducer TGF-β suppresses 
the transcription of enzymes involved in lipogenesis, including 
FASN and acetyl-CoA carboxylase (ACC) (151). These enzymes 
are controlled by the carbohydrate-responsive element-binding 
protein (ChREBP) and sterol regulatory element-binding pro-
teins (SREBPs). Snail1 mediated the suppression of the lipogenic 
program by repressing SREBPs and ChREBP levels. In addition 
to a decreased lipogenesis, TGF-β-induced EMT also promoted 
higher oxygen consumption and elevated intracellular ATP. 
Indeed, decreased FAs synthesis could divert acetyl-CoA into 
the catabolic pathways, e.g., TCA cycle and OXPHOS, which 
efficiently yield high amount of energy to support the elevated 
cell migration required for metastatic spreading. In addition, 
an increased availability of acetyl-CoA could foster histone 
acetylation/activation of genes responsible for EMT engagement, 
i.e., the transcription factors ZEB1, ZEB2, and Slug; the mesen-
chymal markers vimentin, N-cadherin, and fibronectin; and the 
CSC markers Sox2 and Nanog (152). Notably, the expression of 
the lipogenic enzymes FASN and ACC are downregulated in 
circulating cancer cells, when compared to their primary cancer 
counterpart (153). Interestingly, this metabolic switch toward 
a catabolic signature is reversible upon withdrawal of EMT-
inducing stimuli. The functional role of this metabolic reversion is 
that, when metastatic cells finally localize to secondary sites, they 
have the potential to re-activate FASN expression, switching their 
metabolism back to lipogenic pathways, in order to sustain rapid 
cell proliferation and metastatic colonies formation. The obser-
vation that decreased lipogenesis might stimulate cell invasion 
and metastases raises significant attention in considering FASN 
targeting and/or other lipogenic enzymes as potential therapeutic 
target for cancer treatment. Indeed, this therapeutic intervention, 
besides inducing a temporary cancer growth inhibition could, in 
the long-term, increase the risk of metastasis.
Another strategy used by cancer cells to improve FAs avail-
ability for anabolic and catabolic purposes, is to increase the 
expression of acyl-CoA synthetases (ACSLs), which converts 
the long-chain FAs into acyl-CoA, critical for phospholipids and 
TAGs synthesis, lipid modification of proteins as well as for FAs 
β-oxidation (154). In colorectal cancer cells, the simultaneous 
overexpression of ACSL1, ACSL4, and stearoyl-CoA desatu-
rase-1 (SCD), the rate-limiting enzyme converting saturated FAs 
into monounsaturated FAs, induced EMT and increased cellular 
migration and invasion (155). Furthermore, the combination 
of low doses of pharmacological inhibitors of ACSL and SCD 
selectively reduces cell viability of chemotherapy resistant colo-
rectal cells, with no effects on normal colonocytes. The clinical 
relevance of these findings is emphasized in colorectal patients 
with tumors displaying ACSL1/ACSL4/SCD simultaneous 
overexpression, that show a poorer outcome and a higher risk 
of relapse compared to other patients within the same clinico-
pathological stage.
In addition to the above discussed increase in TAGs, a reduc-
tion of C16:0 ceramide levels was also associated with EMT 
(148, 156). A recent study documented that TGF-β-induced 
EMT in human breast epithelial cells downregulates the expres-
sion of ceramide synthase 6 (CerS6), which produces C16:0 
ceramide, further metabolized to C16:0 sphingolipids, such as 
sphingomyelin and glycosphingolipids, both enriched in the 
PM microdomains (156). CerS6 mRNA and protein levels are 
also reduced in TNBC mesenchymal cells as compared with 
non-TNBC epithelial cells. Downregulation of CerS6 in TNBC 
patients correlates with increased PM fluidity, a required feature 
to foster cell motility and metastatic spreading. Hence, CerS6 is 
emerging as a novel EMT-regulated gene, whose reduction in 
cancer correlates with a mesenchymal phenotype and, in turn, 
with tumor aggressiveness and poor prognosis. Accordingly, it 
is predictable that in patients with aggressive TNBC character-
ized by CerS6 downregulation, increasing the levels of C16:0 
ceramide could impair the metastatic potential of this aggressive 
breast cancer subtype.
Further evidence indicates that EMT is associated with 
changes in sphingolipids metabolism. Guan and colleagues 
reported that EMT is associated with the alteration of ganglioside 
(i.e., sialic acid-containing glycosphingolipids) metabolism in 
normal mouse mammary gland and bladder cancer (157). Gg4 is 
one of the most relevant ganglioside involved in EMT execution, 
whose content is reduced upon TGF-β-induced EMT. Gg4 was 
reported to physically interact with key epithelial cell molecules, 
such as E-cadherin and β-catenin, likely facilitating epithelial 
intercellular adhesion via stabilization of the E-cadherin/β-
catenin complex at the cell surface (157). The modulation of 
ganglioside pattern upon EMT is related, at least in part, to the 
altered expression of genes encoding ganglioside metabolizing 
enzymes, which are under the control of different transcription 
factors involved in EMT (i.e., Snail1, Twist, ZEB1) (158–160). 
FiGURe 3 | epithelial-to-mesenchymal transition (eMT) and lipid metabolism: interconnection and targeting. Several EMT-induced stimuli modulate the 
content of different classes of lipids, with an impact on both cell metabolism and membrane composition. Some EMT inducers [i.e., tumor necrosis factor-α (TNF-α), 
hepatocyte growth factor (HGF)] promote lipogenesis by stimulating fatty acid synthase (FASN) and leading to an increase in glicerophospholipids (which are 
transferred to the cell membrane and regulate lipid rafts organization) and in triacylglycerol [stored in lipid drops as a reservoir of fatty acids (FAs) for catabolic or 
anabolic purpose]. On the other hand, other reports support a role for transforming growth factor-β (TGF-β)-derived Snail1 in the suppression of the lipogenic 
program by repressing FASN expression, thus diverting acetyl-CoA toward catabolic pathways, such as the tricarboxylic acid (TCA) cycle. TGF-β-induced EMT also 
correlates with a reduction in the pool of sphingolipids by (i) the downregulation of the expression of ceramide synthase, which results in the reduction of ceramide 
levels; (ii) the lowering of ganglioside content due to the control of EMT-related transcription factors (i.e., SNAIL1, Twist, Zeb1) on the expression of genes encoding 
ganglioside metabolizing enzymes. These events result in an increase of plasma membrane fluidity and destabilization of lipid rafts, to which significantly concurs 
also the upregulation of cholesterol content. Pharmacological inhibitors of cholesterol synthesis (i.e., statins), the administration of alkyl phospholipid drugs (the 
so-called “dis-rafters”), and nutritional factors, such as the ω-3 polyunsaturated FA docosahexaenoic acid, result in the stabilization of lipid raft and in the reduction 
of membrane fluidity, thereby counteracting EMT, invasion, and the acquisition of stem-like features.
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Alongside the role of gangliosides, an involvement of sphin-
gosine-1-phosphate (S1P) in EMT has also been reported. In 
hepatocellular carcinoma, where high levels of S1P in the serum 
correlate with poor prognosis (161), S1P activates the PI3K/AKT 
signaling pathway, resulting in MMP-7 upregulation. MMP-7 
mediates the shedding of syndecan-1, a transmembrane heparan 
sulfate proteoglycan that regulate cell–matrix interaction, with 
a consequent increase in TGF-β1 production, a well-established 
inducer of EMT (162). A role of S1P in the modulation of other 
MMPs which promote cell invasion, such as MMP-2 and MMP-
9, has also been proposed (163, 164).
In parallel with the acquisition of an aggressive phenotype, 
the EMT is marked by a profound rewiring of cell signaling 
pathways, most of them originating from PM located media-
tors (165, 166). It is therefore conceivable that alterations in 
the properties of the PM may impact on the overall signaling 
network rearrangements associated with EMT. Recent evidence 
showed that EMT is associated with a reorganization of the PM 
and in particular with a destabilization of lipid raft domains 
(Figure 3) (167). Alterations of the PM biophysical properties 
are required to maintain the mesenchymal state, associated 
with a CSC phenotype, and an increase in metastatic potential. 
Interestingly, stabilization of lipid rafts is emerging as a target for 
therapeutic strategies aimed to reduce the metastatic potential 
driven by EMT in cancer. The stabilization of lipid raft domains 
is a therapeutically attractive approach, since a number of 
pharmacological and nutritional factors have been shown to 
positively affect raft stability and function (168, 169). Among 
them, the essential ω-3 polyunsaturated FA docosahexaenoic 
acid (DHA) has been recently discovered to stabilize lipid raft 
and to antagonize both EMT and the acquisition of stem-like 
features (170). It suggests that the PM properties are subject 
to dietary inputs and that long-term perturbations in lipid 
metabolism (e.g., hypercholesterolemia, DHA supplementa-
tion) may profoundly affect tumor progression. In addition, 
alkylphospholipid drugs (i.e., miltefosine and edelfosine) that 
have been described as “dis-rafters” for their ability to affect raft 
organization have potent anti-neoplastic activity (169).
To reinforce the link between PM composition and EMT, 
alterations in membrane fluidity, e.g., by modulating cholesterol 
content (Figure  3), has been shown to induce or inhibit the 
conversion toward a mesenchymal phenotype (167). Indeed, 
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the lipid compositions of epithelial or mesenchymal cells are 
distinct (171) and when a given cell undergo the EMT process 
it exhibits a significant increase in cholesterol content, which 
strongly contributes, together with the reduction in ceramide 
pool, to the enhancement in membrane fluidity. Accordingly, 
cancer cells undergoing EMT are more sensitive to cholesterol 
lowering drugs, such as statins, that have been reported to 
deplete cholesterol content in mesenchymal cells, thereby 
reducing PM fluidity and impairing cell motility and metastatic 
potential (172). Increased membrane fluidity is an emerging 
necessary feature of metastatic cancers that can be controlled by 
many currently available drugs, offering a feasible therapeutic 
opportunity to prevent cancer metastasis. A fascinating study 
has recently identified, using an in silico drug screening, a series 
of pharmacological compounds that can repress the metastatic 
phenotype of cancer cells by inhibiting a gene expression sig-
nature associated with EMT. The compounds discovered using 
this analysis, including previously acknowledged anti-metastatic 
drugs, appeared to restrict the metastatic capacity through a 
common mechanism, i.e., the ability to modulate the fluidity 
of cell membranes (173). In keeping, the treatment of breast 
cancer cell lines with some of these anti-metastatic agents (i.e., 
alprostadil, amitriptyline, haloperidol, and maprotiline, as well 
as, salinomycin and thioridazine) reduced membrane fluidity, 
resulting in EMT impairment, decreased cell motility, and stem 
cell-like properties, culminating in the impairment of spontane-
ous metastasis in animal models, thus validating the in  silico 
analysis. The impact of fluidity on the metastatic behavior and 
the strict correlation between membrane fluidity and cholesterol 
content was further supported by the finding that in breast can-
cer patients, the overexpression of the cholesterol efflux channel 
ABCA1 was associated with increased metastatic success and 
was revealed in 41% of metastatic tumors (173).
Role and Targeting of TCA Cycle 
intermediates and OXPHOS in eMT
Although the contribution of mitochondria to the pathogenesis 
of cancer was underestimated for a long time, it is now established 
that mitochondria have an essential role during tumorigenesis. 
Indeed, mitochondrial alterations are essential for the metabolic 
rewiring that characterized a given cancer cells and play a role in 
a series of additional cellular processes during the development 
and progression of cancer.
We have discussed in details in the first paragraph how 
aerobic glycolysis is extensively exploited by rapidly proliferating 
cancer cells to meet their energetic demands and to accumulate 
biosynthetic precursors. However, several reports support the 
opposite notion, i.e., that the metabolic requirements of inva-
sive and metastatic cancer cells are characterized by enhanced 
mitochondrial respiration and ATP generation. This review 
does not discuss whether and what are the circumstances in 
which glycolysis or OXPHOS are exploited by cancer cells for 
promoting their survival and distant colonization. However, we 
would like to emphasize that contradictory results described the 
metabolic phenotype of invasive EMT-committed cancer cells 
as glycolytic or OXPHOS addicted, not only in various tumor 
types, but also within individual cancer types. As confirmed by 
clinical analysis of human invasive breast cancers, the transcrip-
tion coactivator PGC-1α is overexpressed in invasive cancer cells 
and stimulates mitochondrial biogenesis and OXPHOS during 
their transit to metastatic sites (153). PGC-1α silencing in cancer 
cells significantly impaired their invasion ability and decreased 
the frequency of metastasis without affecting cell proliferation 
and primary tumor growth. Notably, the PGC-1α-induced meta-
bolic conversion toward OXPHOS is synergistically coupled to 
a functional EMT program and although PGC-1α-induced 
pathways are not essential for cancer cells during the acquisition 
of a mesenchymal phenotype, both pathways concur and cor-
relate with the achievement of invasive and metastatic properties 
(153).
Accordingly, in both mouse melanoma and human breast 
cancer models, an overloading of the mitochondrial electron 
transport chain (ETC) was reported to promote an invasive 
tumor phenotype associated with increased mitochondrial reac-
tive oxygen species (mtROS) generation (174, 175). However, this 
study underlined that a dysfunctional mitochondrial activity and 
a partial lowering of ETC activity strictly resembled ETC over-
loading, generating a similar pro-oxidant mitochondrial milieu. 
In both cases, superoxide generation induced mitochondrial Src 
activation, which enhanced the expression of Pyk2, a FAK family 
member protein tyrosine kinase that was previously reported 
to promote EMT and migratory abilities (174, 176). Targeting 
mtROS generation by treating with inhibitors of the ETC Complex 
I activity (Ebselen) or using specific mitochondria-targeted 
antioxidants [MitoTEMPO or MitoQ, a mitochondria-targeted 
form of coenzyme Q10 currently tested in clinical trials (177)] 
was sufficient to abolish metastasis formation in vivo (174).
Although mitochondrial superoxide acts as an inducer/sus-
tainer of EMT, an uncontrolled production of this pro-oxidant 
can shift cell fate toward senescence or cell death (178, 179). 
To maintain ROS generation to levels that allow EMT execu-
tion, mitochondrial superoxide dismutase 2 (SOD2) have been 
found upregulated upon TGF-β-mediated EMT, prompting the 
conversion toward a CSC-like phenotype during the early stage 
of EMT (180). ZEB2, but not ZEB1, together with NF-κB seems 
to control the transcriptional regulation of SOD2. In addition, a 
positive feedback loop has been described between SOD2 and 
NF-κB during EMT in lung adenocarcinoma cells: NF-κB can 
promote SOD2 transcriptional activation and concomitantly 
SOD2 induces EMT activating the axis NF-κB/IκB kinase β 
(IKKβ) (181).
Since an overloading of the respiratory mitochondrial metab-
olism is often associated with EMT and with the acquisition of 
pro-invasive skills by cancer cells, drugs that inhibit OXPHOS 
may be proposed as effective strategies to cope with the acquisi-
tion of a motile mesenchymal phenotype endowed with CSC-like 
features and metastatic competency. Arsenic trioxide, which 
interfere with OXPHOS by inhibiting the complex III of ETC and 
metformin, acting on complex I are FDA-approved treatments 
already used in the clinical practice (182, 183). Crucially, arse-
nic trioxide has been proposed for the clinical management of 
relapsed or refractory acute promyelocytic leukemia (183), while 
metformin particularly exerts anticancer activity in patients with 
breast, endometrial, or prostate cancer (184, 185).
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However, a recent study reported data that partially disagree 
with the preeminent role of OXPHOS for metastatic potential of 
cancer cells. In this study, the authors compared mRNA expres-
sion of metabolic genes in 20 different solid cancers to investigate 
the link between metabolic transformation of cancer cells and 
patient prognosis (186). Data revealed that the inhibition of 
mitochondrial metabolism is a common signature for all the 
cancer samples. The downregulation of OXPHOS-related genes 
correlates with metastatic potential and poor clinical outcome 
across several cancer types and it is associated with the presence 
of EMT (186). These results support previous finding that partial 
mitochondrial dysfunction increases metastatic potential of 
cancer cells (174) and encourage future investigations on the role 
of dysregulated metabolism during tumor progression, in order 
to suggest more suitable targets for clinical intervention.
One of the main metabolic pathways active within mitochon-
dria is the TCA cycle. Numerous enzymes of the TCA cycle show 
mutation or deregulated expression pattern in both sporadic and 
hereditary cancers. These alterations identify a subset of patients 
characterized by poor prognosis (187, 188) and sometimes 
specific alterations of these mitochondrial enzymes are directly 
linked to EMT induction.
Consistent with the frequent metabolic rewiring toward 
OXPHOS observed in invasive cancer cells, epithelial cells that 
have activated the EMT program may increase the amount of 
glucose diverted into the TCA cycle by regulating the pyruvate 
dehydrogenase (PDH) complex, the gatekeeper of the cycle. In 
particular, in lung cancer cells the execution of the EMT program 
is accompanied by a downregulation of pyruvate dehydrogenase 
kinase 4 (PDK4) expression levels, which results in an increase 
of PDH activity (189). Downregulation of PDK4 is sufficient to 
drive EMT and promotes erlotinib resistance in EGFR mutant 
lung cancer cells. In keeping, analysis of human lung adenoma 
tumor samples reveals PDK4 suppression as a predictor of poor 
prognosis, consistent with its role during EMT (189).
Besides the deregulation of the expression, specific cancer-
associated mutations of some enzymes of the TCA cycle, associ-
ated with an alteration of their catalytic function, have been also 
recognized. Among the mutated enzymes, the most characterized 
are those involved in the generation of the so-called oncometabo-
lites, including isocitrate dehydrogenase (IDH) (190), succinate 
dehydrogenase (SDH) (191), and fumarate hydratase (FH) (191).
Isocitrate dehydrogenase catalyzes the reversible conversion 
of isocitrate into α-KG. Three isoforms of the enzymes have 
been identified: the NADPH-dependent IDH1 and IDH2 and 
the NADH-dependent IDH3. Mutations in the cytoplasmic 
IDH1 and in the mitochondrial IDH2 mutations occur in vari-
ous human cancers, including gliomas, glioblastoma, and acute 
myelogenous leukemias (AMLs) (192–194). The mutated forms 
of the enzymes reduce α-KG into the d-2-hydroxyglutarate 
(d-2HG). d-2HG levels are low in normal tissues but can reach 
higher concentration levels (up to millimolar) in IDH1 or 
IDH2-mutated tumors. High levels of d-2HG interfere with the 
function of α-KG-dependent dioxygenases, including prolyl 
hydroxylases (PHDs), essential for the regulation of the stability 
of HIFs, Jumonji family of histone demethylases, and TET fam-
ily of DNA demethylases, whose inhibition inevitably impacts 
on the epigenetic control of gene expression (195, 196). High 
d-2HG levels paralleled by an altered epigenetic fingerprint 
was also described in breast tumors characterized by c-Myc 
overexpression and subsequent metabolic reprogramming, 
independently of IDH mutations (197). The enantiomer l-2HG 
(L2HG) can be generated by the non-canonical activity of malate 
dehydrogenase and LDH and not by the IDH1-/IDH2-mutated 
enzymes (198, 199). Recently, in colorectal cancer cells an 
elevation of both d-2HG and its enantiomer l-2HG has been 
observed in the absence of IDH mutations and it is promoted 
by glutamine anaplerosis. It has been reported that only d-2HG 
is able to increase the histone H3 methylation pattern of the 
ZEB1 promoter region, resulting in a direct upregulation of 
ZEB1 and downregulation of miR-200, two key drivers of the 
EMT process (200, 201). Clinical specimens with higher levels 
of d-2HG associate with colonization of distant organs, sup-
porting the significant contribution of this metabolite in cancer 
metastasis. Treatment strategies designed to reduce the levels of 
d-2HG or inhibiting its downstream effects could be effective in 
colorectal cancer. Interestingly, 2HG has been reported as one 
of the few metabolites whose levels are reduced upon aspirin 
administration, currently the most effective drug available for 
chemoprevention of colorectal cancer (202), suggesting d-2HG 
as a potential target for therapeutic intervention, with low risk 
of side effects, since the physiological role of this metabolite is 
not known. IDH-mutated tumors represent the perfect scenario 
to test the specific targeting of tumor metabolism with minimal 
interference with that of normal cells. Inhibitors of the mutant 
form of IDH have been tested glioma and AML patients harbor-
ing IDH mutations (202).
The other two oncometabolites that exert their effects out-
side of the conventional metabolic network are succinate and 
fumarate, two TCA cycle intermediates which reach elevated 
concentrations in some tumors as a consequence of loss-of-
function mutations in the SDH complex or the FH, respectively 
(203–205). Like d-2HG, succinate and fumarate have been found 
to interfere with dioxygenase activity, underlining the oncogenic 
role of both these metabolites in the inhibition of PHDs and 
the subsequent stabilization of HIF-1 (206) and supporting the 
notion that a general property of oncometabolites is the ability to 
regulate epigenetics (191, 207).
Interestingly, fumarate possesses another unique property 
linked to its chemical structure. Indeed, fumarate can covalently 
bind to cysteine residues of proteins in a process called succina-
tion (208, 209). Several proteins are succinated in FH-deficient 
cells, including aconitase (210), Kelch-like ECH-associated 
protein 1 (208, 209), and glutathione (211). Notably, in a subset 
of FH-deficient human renal cell carcinomas, fumarate at high 
concentration directly bounds the antioxidant glutathione 
both in  vitro and in  vivo to produce the metabolite succinated 
glutathione (211). Succinated glutathione acts as an alternative 
substrate to glutathione reductase to decrease NADPH levels and 
enhance mtROS and HIF-1 activation, two mandatory events 
fostering EMT execution.
More recently, Sciacovelli and colleagues demonstrate a 
fascinating role of fumarate, which accumulates in FH-deficient 
renal cancers, in the epigenetic suppression of miR-200 through 
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the inhibition of Tet-mediated demethylation of a regulatory 
region of the anti-metastatic miRNA cluster mir-200ba429 (212). 
Fumarate-dependent miR-200 downregulation leads to the 
expression of EMT-related transcription factors and enhanced 
aggressive features and it is associated with a poor clinical 
outcome (212). Although it has been extensively reported that 
FH deficiency is associated to fumarate-dependent epigenetic 
deregulation, supporting the notion of FH as a tumor suppres-
sor, the molecular mechanisms by which FH gene expression is 
controlled is not well clarified. It has been recently reported that 
in nasopharyngeal carcinoma, the chromatin remodeling factor 
lymphoid-specific helicase binds the FH promoter and recruits 
the epigenetic silencer factor G9a to inhibit the transcription of 
FH (213). The FH reduction promoted an unbalance in the TCA 
intermediates, with a decrease in malate levels and a concomitant 
increase in αKG amount. Deregulation of TCA metabolites in 
nasopharyngeal carcinoma cells induces the recruitment of IKKα 
to the promoter regions of genes involved in the EMT program, 
causing the downregulation of E-cadherin and ZO-1 and the 
parallel upregulation of the mesenchymal marker vimentin, 
leading to EMT, migration and invasion in  vitro, and increase 
metastasis in vivo (213).
Deregulation of different components of the SDH complex, 
enzyme involved in both the ETC and the TCA cycle, have been 
reported in several cancer types (214, 215). SDH is composed of 
four essential subunits: the flavoprotein SDHA, the iron-sulfur 
protein SDHB, and two units anchored to the mitochondrial 
membrane SDHC and SDHD. Mutations in SDHx genes (encod-
ing SDH subunits) lead to succinate accumulation that inhibits 
DNA demethylases (TET enzymes), leading to a global hyper-
methylation of DNA (191, 216, 217). Crucially, SDHx mutations 
have been associated with EMT in hereditary pheochromocy-
toma and paraganglioma, as a result of epigenetic alterations 
(218, 219). In particular, Aspuria et al. demonstrated that Sdhb 
knockdown in mouse ovarian cancer cells resulted in a global 
hypermethylation pattern that promotes EMT and induces a 
metabolic reprogramming of the central carbon metabolism, 
together with additional mitochondrial dysfunction, ultimately 
leading to altered glucose and glutamine utilization (220). More 
recently, Loriot and colleagues clarified how the succinate-
mediated epigenetic modulation impacts on EMT. First, using 
transcriptome profiling of a large cohort of metastatic pheo-
chromocytomas and paragangliomas, the authors reported that 
SDHB-malignant samples displayed a change in the expression 
pattern of Twist1, Twist2, Snail1, and N-cadherin, all indications 
of EMT program activation (221). Moreover, cytokeratin 19 
(KRT19), a component of the intermediate filaments, already 
implicated in conferring enhanced migratory and invasive 
properties in squamous cell carcinomas, neuroblastomas, renal, 
and breast cancers (222–225), has been identified as one of the 
most significantly hypermethylated and downregulated gene in 
SDHB-deficient mouse chromaffin cells, supporting the EMT-
dependent invasive properties and the metastatic behavior of 
these neuroendocrine cancer cells (218).
Besides the four subunits that constitute the SDH complex, 
SDH5 has been identified as a mitochondrial protein necessary 
for the flavination of SDHA and for the assembly of the SDH 
complex. Additionally, several independent reports pointed to a 
role of SDH5 as a tumor-suppressor gene and SDH5 deregulated 
expression correlate with higher tumor incidence (226–228). 
An interesting study reported that SDH5 loss in lung cancers 
promotes tumor aggressiveness and metastasis, hence providing 
an additional functional support on the link between SDH5 and 
EMT. In particular, SDH5 acts as a modulator of the glycogen 
synthase kinase 3β (GSK-3β)/β-catenin signaling, since the 
physical interaction between SDH5 and GSK-3β induces GSK-
3β dephosphorylation/activation, the subsequent decrease of 
β-catenin nuclear accumulation and activation, thereby ultimately 
inhibiting Wnt-β-catenin signaling (229). The downregulation of 
SDH5 observed in lung cancers accounts for the SDH5-mediated 
β-catenin stabilization and transcriptional activity, which in turn 
induces Slug and Twist1 gene expression, thereby repressing 
E-cadherin and contributing to EMT (229).
Besides SDH5 repression, other mitochondrial signaling 
pathways concur to regulate the GSK-3β/β-catenin pathway, 
impacting on EMT. In lung cancer cells, the downregulation of 
the TU translation elongation factor mitochondrial (TUFM), a 
key factor in the translational expression of mitochondrial DNA, 
is associated to the maintenance of the mesenchymal pheno-
type of cancer cells and to the acquisition of more aggressive 
features. TUFM downregulation results in a reduced expression 
of mtDNA, leading to mitochondrial dysfunction and cellular 
stresses such as ATP deficiency and ROS production, which 
trigger AMPK activation. It has been reported that activated 
AMPK induces the phosphorylation of GSK-3β and increases 
the nuclear accumulation of β-catenin, leading to the induction 
of EMT and increased migration and metastatic competency of 
lung cancer cells (230). These results provide a molecular link 
between mitochondrial dysfunction and EMT, which is impli-
cated in lung cancer progression.
Malic enzyme 1 (ME1) is reported to be a major metabolic 
enzyme, both localized in cytosol and mitochondria, catalyzing 
the oxidative decarboxylation of malate into pyruvate, thus fueling 
the TCA cycle, and concomitantly reducing NADP+ into NADPH 
and contributing to macromolecular biosynthesis and protec-
tion from excessive oxidative stress. For its essential metabolic 
roles, ME1 is ubiquitously expressed in different human tissues. 
However, up to now, there are no evidence about its oncological 
functions and clinic significance. A significant upregulation of 
ME1 has been associated to aggressive hepatocellular carcinoma 
and to reduced overall survival and progression-free survival 
in this tumor type (231). Silencing of ME1 in hepatocellular 
carcinoma cells inhibits migration and invasion by blocking the 
EMT program (i.e., restoring E-cadherin while downregulating 
N-cadherin and vimentin expression) in a ROS-dependent way, 
suggesting ME1 as a poor prognostic predictor for hepatocellular 
carcinoma-bearing patients (231).
CONCLUDiNG ReMARKS
Epithelial-to-mesenchymal transition is a specific program that 
confers the cancer cell a series of stem-like properties and migra-
tory abilities thus increasing cancer aggressiveness. The hostile 
microenvironment (i.e., hypoxia, low pH, and low glucose) and 
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the metabolic requirements of a fast-growing tumor sustain EMT 
execution allowing cancer cells to bypass the nutrients and oxygen 
supply limitation caused by the rapid primary cancer growth and 
colonize secondary sites to secure the adequate support of energy 
and nutrients. However, this is not simply a process to acquire 
migration and invasion abilities but a more complex rewiring of 
signaling, metabolic, genetic, and epigenetic networks that allow 
differentiated epithelial cancer cells to revert into a more undiffer-
entiated state and stem cell functions. Additionally, it is plausible 
to speculate that aggressive cancer cells are characterized by 
the ability to undergoing EMT, acquire stem cell-like traits, and 
rewire their metabolism to gain a plethora of strategies to survive 
in different environmental conditions and/or in presence of 
anticancer drugs. This plasticity reinforces the conclusion that “it 
is not the fittest of the species (in this case of the tumor cell bulk) that 
survives but the most adaptable.” The challenges we now face are 
(i) the identification of distinct metabolic hallmarks exclusive to 
cancer-associated EMT and (ii) the identification of therapeutic 
window that allows EMT targeting in cancer patients. These are 
key questions that need to be addressed to reduce the off target 
effects caused by general metabolic therapies and importantly 
to avoid the administration of anti-EMT compounds to cause a 
MET in cells that have already left the primary site and may give 
rise to metastases. However, none of the clinical trials using anti 
metabolic drugs, extensively reviewed in Ref. (6), have investi-
gated whether the effects exerted by these compounds have an 
impact on the EMT process and therefore further confirmation 
in preclinical studies and the design of large prospective clinical 
trials should be planned.
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